5-[2-éthoxy-5-(4-méthyl-1-pipérazinylsulfonyl)phényl]-1-méthyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one

OBS: H et d : ces lettres s'écrivent en italique.

CONT: The 446 Patent disclosure states that the patent relates to the use of a series of pyrazolo [4,3-d]pyrimidin-7-ones for the treatment of impotence. The disclosure then states that the present invention concerns the use of a compound of formula I. Formula I gives rise to approximately 260 quintillion chemical compounds. The disclosure classifies these 260 quintillion compounds into four categories: a preferred group of compounds, a more preferred group of compounds; a particularly preferred group of compounds: and a list of especially preferred individual compounds of the invention. Included in the list of especially preferred individual compounds is 5-[2-ethoxy-5-(4-methyl-1-piperazinyl-sulphonyl)-phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one or a pharmaceutically acceptable salt thereof.
OBS: H and d: these letters must be italicized.